Mesoblast Ltd (MESO) stock

MESONasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends June 30Also trades as MEOBF

Financials through fiscal 2026, year ended Jun 30, 2026Last filing: 20-F on Aug 27, 2026Score 6/30

$13.27+0.17 (+1.30%)

Close on Nov 13, 2026Market cap $1.72BP/E –Yield –

Mesoblast gross margin

Gross margin is gross profit as a percentage of revenue.

For fiscal 2026 it was 86.1%, against 70.2% the year before.

Period	Period end	Value	Change (pts)
FY2026	Jun 30, 2026	86.1%	+16.0
FY2025	Jun 30, 2025	70.2%	−29.8
FY2024	Jun 30, 2024	100.0%	+0.0
FY2023	Jun 30, 2023	100.0%	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is MESO.

Revenue growth599.2% · median 79.6%

Gross margin86.1% · median 35.8%

Net margin-47.8% · median -186.4%

Advertisement
300 × 250

See a number that looks wrong?